Search Within

Heiko Schoder

  1. "Nursing"
Formats
  1. Journal Article (20)
  2. Meeting Abstract (19)
Groups
  1. Molecular Imaging and Therapy Service (39)
  2. Nursing (39)
  3. Radiology, Department of (39)
  4. Department of Medicine (27)
  5. Hematologic Malignancies, Division of (23)
  6. Center for Hematologic Malignancies (22)

More Groups

People
  1. Alison Moskowitz (17)
  2. Andrew Zelenetz (17)
  3. David Straus (17)
  4. Matthew Matasar (16)
  5. Anita Kumar (15)
  6. Craig Moskowitz (15)

More People

Years
  1. 2024 (2)
  2. 2021 (3)
  3. 2019 (2)
  4. 2018 (3)
  5. 2017 (5)
  6. 2016 (3)

More Years

Publications
  1. Blood (11)
  2. Journal of Nuclear Medicine (9)
  3. Journal of Clinical Oncology (7)
  4. Hematological Oncology (3)
  5. International Journal of Radiation Oncology, Biology, Physics (2)
  6. Medical Physics (2)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Society of Nuclear Medicine (9)
  3. American Society of Clinical Oncology (7)
  4. Wiley Blackwell (4)
  5. American Association of Physicists in Medicine (2)
  6. Elsevier Inc. (2)

More Publishers

Results (39)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Cobimetinib-induced “dropped head syndrome” and subsequent disease management in an Erdheim-Chester patient
    Journal Article

    King, A. C.; Diamond, E. L.; Orozco, J. S.; Morse, H. R.; Ouyang, L. L.; Schöder, H.; Rampal, R. K.
    Clinical Case Reports (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save